Medicine
Kengreal 50 mg powder for injection
Kengreal 50 mg powder for injection is a prescription medicine containing Cangrelor for intravenous use, marketed by Chiesi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
NDC # 10122-620-01: 10 mL vial containing 50 mg cangrelor NDC # 10122-620-10…
Key facts
- Active ingredient (INN)
- Cangrelor
- Brand
- Kengreal
- Strength
- 50 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 10 vials
- Marketing authorisation holder
- Chiesi
- Manufacturer
- Chiesi
- Origin register
- US FDA, United States
- Storage
- NDC # 10122-620-01: 10 mL vial containing 50 mg cangrelor NDC # 10122-620-10: 10 count of 10 mL vials containing 50 mg cangrelor Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted].
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AC25 Cangrelor
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 July 2015
- Identifiers
- RxCUI 1656056, 1656061DailyMed set ID 88b434fa-8891-4fd5-9d86-7ea64667c08fNDC 10122-620Application NDA204958
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial, single-use in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-use | 10122-620-10 | Chiesi | 8 July 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Cangrelor 50 mg powder for injection.
Clinical summary
Cangrelor is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients, among other approved uses. MedsAcross supplies Cangrelor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CangrelorFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KENGREAL prescribing information (Chiesi) · U.S. National Library of Medicine, DailyMed
- Kengrexal: European public assessment report (EPAR) · European Medicines Agency
Need Kengreal 50 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.